Pay in 4 interest-free payments of $375.00 Learn more
Ships within 48 hours · Estimated delivery Jul 25 - Jul 30
Background Prefoldin subunit 2
The intensity of the color is positively correlated with the amount of semaphorin-3B (SEMA3B) in the sample
also known as dopa decarboxylase (DDC)
Epub 2016 Apr 21
ActRIIB Enzyme Activity Inhibitor Screening Kit Cell Biology Kits Background Prefoldin subunit 2Product Specification Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibiting the ACTRII signaling pathway has been proven to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving significant fat